Abstract

In 2014, the term Genitourinary Syndrome of Menopause (GSM) was coined to replace formerly termed Vulvovaginal atrophy to include the range of inter-related symptoms. It is frequently underestimated and mostly underreported disorder that requires careful clinical assessment of symptomatology. Other conditions mimicking this condition needs to be ruled out before establishing the diagnosis for an accurate and safe management. The etiology is by far unknown but could be due to interplay of various local and systemic hormonal and inflammatory markers. An extensive PubMed literature search was conducted by the authors to collect recent evidence published after 2015 on the diagnosis and management of GSM. In this review, we attempt to highlight the importance of addressing these concerns by the healthcare professionals and describe the existing therapeutic options.